Search results
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
Zacks via Yahoo Finance· 8 months agoNovartis’ NVS generic arm Sandoz announced that the European Commission (EC) granted marketing...
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Benzinga via Yahoo Finance· 2 weeks agoGeneric and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on...
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Benzinga via Yahoo Finance· 1 year agoAmgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on...
Generic drugmakers Teva and Sandoz make major push to biosimilars
Reuters via Yahoo News· 1 year agoGeneric drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant...
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Benzinga via Yahoo Finance· 1 year agoSandoz, a generic pharmaceuticals and biosimilar unit of Novartis AG (NYSE: NVS), has agreed to...
Amgen sues Novartis to block generic osteoporosis, bone cancer drugs
Reuters via Yahoo Finance· 1 year agoAmgen Inc sued Novartis AG's Sandoz in New Jersey federal court Monday, accusing Sandoz's proposed...
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
Zacks via Yahoo Finance· 2 years agoNovartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and...
Amgen wins appeal in US patent case over generic psoriasis drugs
Reuters via Yahoo Finance· 1 year agoAmgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that barred generic versions...
Sandoz launches rival version of AbbVie's arthritis drug Humira
Reuters via Yahoo Finance· 10 months agoThe Novartis-owned company said its drug, Hyrimoz, will be priced at a 5% discount off Humira’s...
UPDATE 1-Sandoz to buy eye drug Cimerli in $170 million deal
Reuters via Yahoo Finance· 4 months agoSandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million. The drug is interchangeable with Lucentis ...